Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 720 participants.

Also called NCT01644188

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 720 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01644188
  • EudraCT 2011-004130-34
Other papers using this trial's data
  • Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial European heart journal, 2015-05-14 DOI, PubMed 25687353, PMC4430683 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Denmark, France, Hungary, Israel, Russia, South Africa, South Korea, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01644188. Randomized; quadruple masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2015-11-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)
Condition
Hypercholesterolemia
Intervention (Drug)
Alirocumab
Intervention (Drug)
Placebo (for alirocumab)
Intervention (Drug)
Ezetimibe
Intervention (Drug)
Placebo (for ezetimibe)
Intervention (Drug)
Lipid Modifying Therapy (LMT)
Lead sponsor
Sanofi (class: industry)
Collaborator
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01644188
Content hash
57ae53bf9839fbbc6c87604a80f38263a5514d8e3fe05c0ac73618abbf5deb39